- Home
- LPTX vs ERH Comparison
LPTX vs ERH Comparison
Compare LPTX & ERH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- ERH
- Stock Information
- Founded
- LPTX 2011
- ERH 2004
- Country
- LPTX United States
- ERH United States
- Employees
- LPTX N/A
- ERH N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- ERH Finance/Investors Services
- Sector
- LPTX Health Care
- ERH Finance
- Exchange
- LPTX Nasdaq
- ERH Nasdaq
- Market Cap
- LPTX 119.6M
- ERH 97.6M
- IPO Year
- LPTX N/A
- ERH N/A
- Fundamental
- Price
- LPTX $0.37
- ERH $11.10
- Analyst Decision
- LPTX Buy
- ERH
- Analyst Count
- LPTX 2
- ERH 0
- Target Price
- LPTX $8.00
- ERH N/A
- AVG Volume (30 Days)
- LPTX 381.5K
- ERH 23.2K
- Earning Date
- LPTX 05-20-2025
- ERH 01-01-0001
- Dividend Yield
- LPTX N/A
- ERH 8.85%
- EPS Growth
- LPTX N/A
- ERH N/A
- EPS
- LPTX N/A
- ERH N/A
- Revenue
- LPTX N/A
- ERH N/A
- Revenue This Year
- LPTX N/A
- ERH N/A
- Revenue Next Year
- LPTX N/A
- ERH N/A
- P/E Ratio
- LPTX N/A
- ERH N/A
- Revenue Growth
- LPTX N/A
- ERH N/A
- 52 Week Low
- LPTX $0.22
- ERH $7.97
- 52 Week High
- LPTX $4.79
- ERH $10.91
- Technical
- Relative Strength Index (RSI)
- LPTX 45.04
- ERH 61.89
- Support Level
- LPTX $0.32
- ERH $10.56
- Resistance Level
- LPTX $0.38
- ERH $11.22
- Average True Range (ATR)
- LPTX 0.03
- ERH 0.21
- MACD
- LPTX 0.00
- ERH 0.07
- Stochastic Oscillator
- LPTX 37.36
- ERH 90.16
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About ERH Allspring Utilities and High Income Fund
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.